Geron Drug Lands a First-in-Class FDA Approval in Type of Blood Cancer
Posted
Frank Vinluan (via MedCity News)
Geron Corporation’s Rytelo is now FDA approved for treating anemia caused by myelodysplastic syndromes. The new drug will compete against Reblozyl, a blockbuster Bristol Myers Squibb medicine.
The post Geron Drug Lands a First-in-Class FDA Approval in Type of Blood Cancer appeared first on MedCity News.
